5,673 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Bridgewater Associates LP

Bridgewater Associates LP purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,673 shares of the company's stock, valued at approximately $674,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company's stock valued at $41,000 after purchasing an additional 238 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after purchasing an additional 252 shares during the period. Planning Capital Management Corp grew its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after acquiring an additional 388 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in shares of BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock valued at $155,000 after acquiring an additional 1,562 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group upgraded BioNTech from a "neutral" rating to a "buy" rating and raised their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. JPMorgan Chase & Co. decreased their price objective on BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a report on Tuesday, November 26th. Jefferies Financial Group upgraded BioNTech from a "hold" rating to a "buy" rating and raised their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Bank of America raised their price objective on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a report on Monday, September 16th. Finally, Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.67.

BioNTech Price Performance

Shares of NASDAQ BNTX traded down $1.61 during midday trading on Tuesday, reaching $115.59. The company's stock had a trading volume of 578,990 shares, compared to its average volume of 813,281. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a market cap of $27.71 billion, a P/E ratio of -56.11 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The business's 50 day moving average price is $113.89 and its two-hundred day moving average price is $98.94.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period in the previous year, the business earned $0.73 earnings per share. The company's revenue was up 38.9% on a year-over-year basis. On average, analysts forecast that BioNTech SE will post -3.72 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.